Evidence map›Paper›PMID 41542593›Full record

ArticlebioRxiv : the preprint server for biology2026

Small molecule stabilization of diverse amyloidogenic immunoglobulin light chains revealed by hydrogen-deuterium exchange mass spectrometry.

Daniele Peterle, Nicholas L Yan, Elena S Klimtchuk, Thomas E Wales, Olga Gursky, Jeffery W Kelly, John R Engen, Gareth J Morgan

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Daniele PeterleDepartment of Chemistry & Chemical Biology, Northeastern University, Boston, MA, USA.ORCID 0000-0002-9960-1054
Nicholas L YanDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0003-4978-550X
Elena S KlimtchukAmyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0009-0004-0254-0550
Thomas E WalesDepartment of Chemistry & Chemical Biology, Northeastern University, Boston, MA, USA.ORCID 0000-0001-6133-5689
Olga GurskyDepartment of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-8598-4824
Jeffery W KellyDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-8943-3395
John R EngenDepartment of Chemistry & Chemical Biology, Northeastern University, Boston, MA, USA.ORCID 0000-0002-6918-9476
Gareth J MorganAmyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-1275-2010

Funding

Structural Thermodynamics of Human Apolipoprotein C-1R01GM067260 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GURSKY, OLGA · 2003 to 2024
$7.4M
Probing the Proteinopathy Component of Light Chain Amyloidosis PharmacologicallyR01HL157566 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI JEFFERY W KELLY · 2021 to 2026
$3.3M
Structure and Function of Serum Amyloid A in Health and DiseaseR01GM135158 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Olga Gursky · 2020 to 2026
$2.4M
NHLBI NIH HHS R01 HL157566NIGMS NIH HHS R01 GM067260NIGMS NIH HHS R01 GM135158
6 · The paper itself

Abstract

Immunoglobulin light chains, a component of antibodies, can misfold and aggregate to cause systemic AL amyloidosis. Aggregation, including amyloid fibril formation, requires unfolding of the full-length light chain from its native state, and in most cases aberrant proteolysis. Small molecules that bind to the native state of light chains to stabilize them against conformational excursions and proteolysis are under development as drug candidates for AL amyloidosis. Since each patient has a unique light chain sequence, a challenge for candidate stabilizer drugs is to bind multiple light chains and suppress their dynamics. Here, we used hydrogen-deuterium exchange measured by mass spectrometry to characterize the binding of six small molecule stabilizers to eleven different λ light chain proteins. Despite structural and dynamic differences among the light chains, the binding of the most efficacious stabilizer molecule led to increased protection from hydrogen exchange, consistent with reduced local and global unfolding. Protection upon binding was most prominent in residues within complementarity determining region 3 and framework region 4 of the light chain variable domains, which undergo major conformational changes enabling amyloid formation. Stabilizer binding also reduced the rate at which all light chains were cleaved by protease. These data show that these stabilizers suppress the range of conformational dynamics associated with light chain aggregation, supporting their therapeutic potential.

Indexed as

AL amyloidosisamyloid fibrilsdrug designHDX-MSImmunoglobulin light chain amyloidosisLight chain kinetic stabilizersPLIMSTEX analysisprotein stability and dynamics

Identifiers

PMID41542593
PMCPMC12803214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.